Indeed, it has already been observed that high ERRα gene expression correlates with unfavorable clinical outcomes in breast [32] and ovarian cancer [14, 33] and that breast cancer cells exhibiting high ERRα activity are more sensitive to growth inhibition by an ERRα inverse agonist such as XCT790 [34]. This evidence concerns the gene ESRRA and breast carcinoma.